Role of dexamethasone in the prevention of migraine recurrence in the acute care setting: A review

Postgraduate Medicine

Volumn 124, Issue 3, 2012, Pages 110-115

  Giuliano, Christopher ^a   Smalligan, Roger D ^b   Mitchon, Greg ^b   Chua, Matt ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Dexamethasone; Emergency department; Migraine; Prevention; Recurrence; Steroid

Indexed keywords

ACETYLSALICYLIC ACID; ANTIEMETIC AGENT; CHLORPROMAZINE; DEXAMETHASONE; DIHYDROERGOTAMINE; DIPHENHYDRAMINE; ERGOT ALKALOID; KETOROLAC; METOCLOPRAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PETHIDINE; PHENOTHIAZINE; PLACEBO; PREDNISONE; PROCHLORPERAZINE; PROMETHAZINE; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ANTIINFLAMMATORY AGENT;

AGE; ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EMERGENCY CARE; FOLLOW UP; GENDER; HUMAN; META ANALYSIS (TOPIC); MIGRAINE; PAIN ASSESSMENT; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; CLASSIFICATION; CLINICAL TRIAL (TOPIC); REVIEW;

ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; DEXAMETHASONE; HUMANS; MIGRAINE DISORDERS; PAIN MEASUREMENT; RECURRENCE;

EID: 84867890234     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.05.2554     Document Type: Article

References (33)

1. Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med. 2002;39(3):215-222.
2. Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF. A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992;19(3):333-339.
3. Stewart WF, Simon D, Shechter A, Lipton RB. Population variation in migraine prevalence: a meta-analysis. J Clin Epidemiol. 1995;48(2):269-280.
4. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267(1):64-69.
5. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349.
6. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-657.
7. Hazard E, Munakata J, Bigal ME, Rupnow MF, Lipton RB. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value Health. 2009;12(1):55-64.
8. Gerth WC, Carides GW, Dasbach EJ, Visser WH, Santanello NC. The multinational impact of migraine symptoms on healthcare utilisation and work loss. Pharmacoeconomics. 2001;19(2):197-206.
9. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992;2(1):67-76.
10. Ducharme J, Beveridge RC, Lee JS, Beaulieu S. Emergency management of migraine: is the headache really over? Acad Emerg Med. 1998;5(9):899-905.
11. Colman I, Rothney A, Wright SC, Zilkalns B, Rowe BH. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology. 2004;62(10):1695-1700.
12. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(suppl 1):9-160.
13. Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336(7657):1359-1361.
14. Singh A, Alter HJ, Zaia B. Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department? A meta-analysis and systematic review of the literature. Acad Emerg Med. 2008;15(12):1223-1233.
15. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. Eur Neurol. 1992;32(3):177-184.
16. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. Eur Neurol. 1991;31(5):314-322.
17. Tfelt-Hansen P. Frovatriptan and data publication. Headache. 2008; 48(9):1382-1383.
18. Dodick DW, Lipton RB, Goadsby PJ, et al. Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database. Headache. 2008;48(2):184-193.
19. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297(13):1443-1454.
20. Gallagher RM. Emergency treatment of intractable migraine. Headache. 1986;26(2):74-75.
21. Krymchantowski AV, Barbosa JS. Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug. Arq Neuropsiquiatr. 2001;59(3-B):708-711.
22. Innes GD, Macphail I, Dillon EC, Metcalfe C, Gao M. Dexamethasone prevents relapse after emergency department treatment of acute migraine: a randomized clinical trial. CJEM. 1999;1(1):26-33.
23. Rowe BH, Colman I, Edmonds ML, Blitz S, Walker A, Wiens S. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache. Headache. 2008;48(3):333-340.
24. Friedman BW, Greenwald P, Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007;69(22):2038-2044.
25. Bigal M, Sheftell F, Tepper S, Tepper D, Ho TW, Rapoport A. A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache. 2008;48(9):1286-1293.
26. Donaldson D, Sundermann R, Jackson R, Bastani A. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial. Am J Emerg Med. 2008;26(2):124-130.
27. Fiesseler FW, Shih R, Szucs P, et al. Steroids for migraine headaches: a randomized double-blind, two-armed, placebo-controlled trial. J Emerg Med. 2011;40(4):463-468.
28. Kelly AM, Kerr D, Clooney M. Impact of oral dexamethasone versus placebo after ED treatment of migraine with phenothiazines on the rate of recurrent headache: a randomised controlled trial. Emerg Med J. 2008;25(1):26-29.
29. Baden EY, Hunter CJ. Intravenous dexamethasone to prevent the recurrence of benign headache after discharge from the emergency department: a randomized, double-blind, placebo-controlled clinical trial. CJEM. 2006;8(6):393-400.
30. Bigal ME, Lipton RB. When migraine progresses: transformed or chronic migraine. Expert Rev Neurother. 2006;6(3):297-306.
31. Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med. 1991;325(5):316-321.
32. Dahlof C. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. Cephalalgia. 1999;19(9):769-778.
33. Texas Tech Pain Scales. http://www.ttuhsc.edu/som/clinic/forms/ACForm3.02.A.pdf. Accessed June 8, 2010.